×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ORTX – orchard therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ORTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
9/20
07:41 am
ortx
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Medium
Report
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
9/18
03:15 pm
ortx
Orchard Therapeutics stock jumps 13% as FDA accepts BLA for OTL-200 [Seeking Alpha]
Neutral
Report
Orchard Therapeutics stock jumps 13% as FDA accepts BLA for OTL-200 [Seeking Alpha]
9/18
07:00 am
ortx
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
High
Report
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
9/12
07:00 am
ortx
FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE
Medium
Report
FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE
9/12
07:00 am
ortx
FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE
Medium
Report
FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE
8/31
07:11 am
ortx
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023 [Yahoo! Finance]
Medium
Report
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023 [Yahoo! Finance]
8/31
07:00 am
ortx
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
Medium
Report
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
8/18
10:54 am
ortx
Private equity firms own 28% of Orchard Therapeutics plc (NASDAQ:ORTX) shares but retail investors control 45% of the company [Yahoo! Finance]
Low
Report
Private equity firms own 28% of Orchard Therapeutics plc (NASDAQ:ORTX) shares but retail investors control 45% of the company [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
9/18
07:08 am
ortx
Form 8-K Orchard Therapeutics For: Sep 18
High
Report
Form 8-K Orchard Therapeutics For: Sep 18
8/22
06:03 am
ortx
Form EFFECT Orchard Therapeutics
Neutral
Report
Form EFFECT Orchard Therapeutics
8/21
04:33 pm
ortx
Form 424B3 Orchard Therapeutics
Neutral
Report
Form 424B3 Orchard Therapeutics
8/10
04:37 pm
ortx
Form 10-Q Orchard Therapeutics For: Jun 30
Medium
Report
Form 10-Q Orchard Therapeutics For: Jun 30
8/3
07:06 am
ortx
Form 8-K Orchard Therapeutics For: Aug 03
Low
Report
Form 8-K Orchard Therapeutics For: Aug 03
6/26
07:06 am
ortx
Form 8-K Orchard Therapeutics For: Jun 26
Medium
Report
Form 8-K Orchard Therapeutics For: Jun 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Form 10-K Orchard Therapeutics For: Dec 31
20.8%
11/6 Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises 9.9%
12/2 Form 6-K Orchard Therapeutics For: Dec 02 7.7%
1/8 Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as Companies are Investing More on Research and Development, Says Absolute Markets Insights 7.1%
10/22 Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation 6.2%
1/9 Orchard Therapeutics PLC - (NASDAQ: ORTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $15.00 price target on the stock. 6.0%
4/9 Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P. 5.3%
4/14 Form PRE 14A Orchard Therapeutics For: Jun 17 4.9%
4/23 Stem Cells Market Outlook with a Focus on Clinical Therapies 2020-2030: Types of Stem Cells, Route of Administration, Therapeutic Areas, End-users, Key Geographical Regions 4.7%
4/3 Form 4 Orchard Therapeutics For: Apr 01 Filed by: THOMAS FRANK E 4.7%
11/6 Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises 9.9%
12/2 Form 6-K Orchard Therapeutics For: Dec 02 7.7%
1/8 Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as Companies are Investing More on Research and Development, Says Absolute Markets Insights 7.1%
10/22 Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation 6.2%
1/9 Orchard Therapeutics PLC - (NASDAQ: ORTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $15.00 price target on the stock. 6.0%
4/9 Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P. 5.3%
4/14 Form PRE 14A Orchard Therapeutics For: Jun 17 4.9%
4/23 Stem Cells Market Outlook with a Focus on Clinical Therapies 2020-2030: Types of Stem Cells, Route of Administration, Therapeutic Areas, End-users, Key Geographical Regions 4.7%
4/3 Form 4 Orchard Therapeutics For: Apr 01 Filed by: THOMAS FRANK E 4.7%
TOP News Decliners
3/18
Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
-16.8%
6/3 Orchard Therapeutics Launches Proposed Public Offering -16.1%
1/29 Form 8-K Orchard Therapeutics For: Jan 29 -9.5%
2/27 Q4/2019 12/31/2019 EPS -0.460 ZacksConsensus -0.440 ActVsEst (0.020) - Miss -7.1%
11/6 Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -6.4%
3/31 Orchard Therapeutics Outlines Business Impact of COVID-19 -6.4%
12/2 Orchard Therapeutics PLC - (NASDAQ: ORTX) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $28.00 price target on the stock. -6.3%
10/10 Viral Vector & Plasmid DNA Report 2019: Technologies and Global Markets, 2018-2024 - ResearchAndMarkets.com -6.3%
12/8 Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting -6.3%
2/29 Orchard Therapeutics PLC (ORTX) CEO Mark Rothera on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
6/3 Orchard Therapeutics Launches Proposed Public Offering -16.1%
1/29 Form 8-K Orchard Therapeutics For: Jan 29 -9.5%
2/27 Q4/2019 12/31/2019 EPS -0.460 ZacksConsensus -0.440 ActVsEst (0.020) - Miss -7.1%
11/6 Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -6.4%
3/31 Orchard Therapeutics Outlines Business Impact of COVID-19 -6.4%
12/2 Orchard Therapeutics PLC - (NASDAQ: ORTX) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $28.00 price target on the stock. -6.3%
10/10 Viral Vector & Plasmid DNA Report 2019: Technologies and Global Markets, 2018-2024 - ResearchAndMarkets.com -6.3%
12/8 Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting -6.3%
2/29 Orchard Therapeutics PLC (ORTX) CEO Mark Rothera on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: